When was Epsilogen founded?

Epsilogen was founded in 2016 and raised its 1st funding round 1 year after it was founded.

Where is Epsilogen located?

Epsilogen is headquartered in London, United Kingdom.

Which legal entities is Epsilogen associated with?

Epsilogen is associated with Epsilogen Ltd.

How many employees does Epsilogen have?

As of Sep 30, 2026, the latest employee count at Epsilogen is 33.

Is Epsilogen a funded company?

Epsilogen is a funded company, having raised a total of $70.3M across 9 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 20, 2017.

When was the latest funding round of Epsilogen?

Epsilogen's latest funding was a $***** Series B round on Sep 09, 2024, with participation from 5 investors.

What is the annual revenue of Epsilogen?

Annual revenue of Epsilogen is less than £1M as on Dec 31, 2024

Where does Epsilogen rank among its competitors?

Epsilogen ranks 590th amongst 3429 active competitors, of which 1143 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Epsilogen?

Epsilogen's top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Immuneel secured the most recent funding round in June, 2026.

Epsilogen - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of immunoglobulin antibodies for the treatment of cancer. It offers antibodies that help in the treatment of solid tumors. The lead product candidate, MOv18 IgE is for folate receptor alpha positive cancer patients. Other products include EPS 201 for breast cancer and gastric problems.

Website: epsilogen.com
Email ID: *****@epsilogen.com
Phone Number: +44 **********

Key Metrics

Founded Year

2016

Location

London, United Kingdom

Stage

Series B

Total Funding

$70.3M in 9 rounds

Latest Funding Round

Series B, Sep 09, 2024, $*****

Investors

Epidarex Capital & 16 more

Ranked

590^th among 3429 active competitors

Annual Revenue

£0 - £1M as on Dec 31, 2024

Employee Count

33 as on Sep 30, 2026

Investment & Acquisitions

TigaTx

Similar Companies

Jazz Pharmaceuticals & 3087 more

View Epsilogen's full profile

Epsilogen is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Epsilogen Ltd CIN: 10295520 , United Kingdom, Active	Jul 25, 2016	£0 - £1M (As on Dec 31, 2024)	4 (As on Dec 31, 2020)

Epsilogen has raised a total funding of $70.3M over 9 rounds. Its first funding round was on Jun 20, 2017. Its latest funding round was a Series B round on Sep 09, 2024 for $*****. 5 investors participated in its latest round. Epsilogen has 14 institutional investors and 3 angel investors.

Here is the list of recent funding rounds of Epsilogen:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 09, 2024	7241964	Series B	8537291	8034145	5079110	4649956
Mar 02, 2022	8843544	Series B	6486975	5747455	8213044	British Patient Capital & 5 more
Oct 22, 2020	7044047	Grant (prize money)	3335661	8408465	3378609	Gov

Access funding benchmarks and valuations. Sign up today!

View details of Epsilogen's funding rounds and investors

Epsilogen's employee count trend

Epsilogen has 33 employees as of Sep 26. Here is Epsilogen's employee count trend over the years:

Uncover Epsilogen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Epsilogen include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Epsilogen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
5th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
6th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
7th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
8th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
590th	Epsilogen 2016, London (United Kingdom), Series B	Developer of immunoglobulinE antibodies for the treatment of cancer	$70.3M	Epidarex Capital, UCL Technology Fund & 15 others	42/100